Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.79 |
| ▸ | HTR1A | P08908 | 2/20 | 0.79 |
| ▸ | HTR2C | P28335 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.57 |
| ▸ | TUBB | P07437 | 2/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134588 | 1.00 | KDM4E (0.79) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| Sinapic Acid Methyl Ether SCHEMBL207442 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| Sinapic Acid Methyl Ether SCHEMBL207441 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| SCHEMBL28914840 | 0.88 | GAA (0.79) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| SCHEMBL30122806 | 0.88 | GAA (0.79) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| Sinapic Acid Methyl Ether SCHEMBL9757598 | 0.87 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| Sinapic Acid Methyl Ether SCHEMBL9848210 | 0.87 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| Sinapic Acid Methyl Ether SCHEMBL30365738 | 0.87 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| Sinapic Acid Methyl Ether SCHEMBL9757606 | 0.87 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10HTR1A | |
| SCHEMBL17211760 | 0.86 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637575-B2 | Modulators of protein kinase signaling | NOVOTYR THERAPEUTICS LTD. (IL) | 2014-01-28 | — | — | US | disclosed |
| US-8536227-B2 | — | — | 2013-09-17 | — | — | US | disclosed |
| US-20110105618-A1 | NOVEL MODULATORS OF PROTEIN KINASE SIGNALING | NOVOTYR THERAPEUTICS LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
| WO-2009147682-A1 | NOVEL MODULATORS OF PROTEIN KINASE SIGNALING | NOVOTYR THERAPEUTICS LTD. (IL) | 2009-12-10 | — | — | WO | disclosed |
| EP-0628311-B1 | Xanthine-Derivatives as Antidepressants | KYOWA HAKKO KOGYO KK (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-0565377-B1 | Therapeutic agents for use in the treatment of Parkinson's Disease | KYOWA HAKKO KOGYO KK (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5587378-A | ADMINISTERING A SUBSTITUTED XANTHINE COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5543415-A | ADMINISTERING A XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-08-06 | — | — | US | disclosed |
| US-5484920-A | XANTHINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| EP-0628311-A1 | ANTIDEPRESSANT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| EP-0565377-A1 | Therapeutic agents for use in the treatment of parkinson's disease | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105618-A1 | NOVEL MODULATORS OF PROTEIN KINASE SIGNALING | MAP3K20, MAP3K1, MAP3K6 | KDM4E 1619/4885ALDH1A1 4678/4885HPGD 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.